Congenica

Cambridge, United Kingdom· Est. 2014

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $99M

Overview

Congenica is a leading provider of clinical genomic interpretation software, trusted by national health systems and over 190 labs worldwide. Its AI-powered platform transforms raw next-generation sequencing (NGS) data into actionable clinical insights, primarily for rare diseases but with expanding capabilities in oncology and infectious disease. Founded in 2014 with deep roots in the UK's Genomics England initiatives, the company was acquired by SeqOne in 2025, combining forces to create a scaled, well-funded entity with significant clinical and technological heritage. Congenica operates a SaaS-based business model, generating revenue by providing its platform and associated clinical interpretation services to diagnostic laboratories.

Rare DiseasesOncologyInfectious Diseases

Technology Platform

AI-powered, cloud-based clinical genomic interpretation platform for analyzing NGS data across rare disease, oncology, and infectious disease. It transforms raw sequencing data into clinical reports with transparent, explainable variant prioritization and classification.

Funding History

Total raised:$99M

Series C$50MTencent HoldingsJan 15, 2022

Series B$39MLegal & General CapitalOct 15, 2019

Series A$10MAmadeus Capital PartnersJun 15, 2015

Opportunities

The global shift towards routine whole genome sequencing in clinical diagnostics represents a massive growth opportunity, as it drastically increases data complexity requiring interpretation.

Furthermore, expanding its integrated platform from a rare disease stronghold into high-volume oncology and infectious disease testing opens large new addressable markets.

The merger with SeqOne provides greater scale, resources, and a complementary product set to accelerate international expansion.

Risk Factors

The company faces significant integration challenges following its acquisition by SeqOne, with potential for operational disruption.

It operates in a fiercely competitive market against well-capitalized players, risking erosion of its technological edge.

Growth is also dependent on the pace of healthcare reimbursement reform for advanced genomic tests and navigating complex, evolving regulatory pathways across different countries.

Competitive Landscape

Congenica competes in the clinical genomics interpretation software market against companies like Sophia Genetics, Fabric Genomics, Qiagen (Ingenuity Pathway Analysis), and Bio-Rad (Bioinformatics). Its key differentiators are its deep clinical heritage from the Sanger Institute and NHS, proven scale in national public health systems, and a platform philosophy emphasizing transparency and explainability for clinical users. The merger with SeqOne strengthens its position against larger, broader diagnostic IT platforms.